Open-Angle Glaucoma Subjects With Cataract Treated With Cataract Surgery Plus One iStent and One iStent Supra
Launched by GLAUKOS CORPORATION · Aug 17, 2017
Trial Information
Current as of May 03, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinically significant cataract requiring surgery Primary open-angle or pseudoexfoliative glaucoma Visual field defects no worse than -12dB Subject on two ocular hypotensive medications at screening Medicated IOP at screening between 18 and 30 mm Hg Normal iridocorneal anatomy Absence of peripheral anterior synechiae
- Exclusion Criteria:
- • Monocular subjects or those with wore than 20/200 vision in fellow eye Prior stent implantation, incision glaucoma surgery, or laser trabeculoplasty in study eye Traumatic, uveitic, or neovascular glaucoma
About Glaukos Corporation
Glaukos Corporation is a pioneering medical technology company dedicated to transforming the treatment of glaucoma and other eye diseases through innovative surgical and drug delivery solutions. With a strong focus on advancing patient care, Glaukos develops cutting-edge minimally invasive therapies that aim to reduce intraocular pressure and improve visual outcomes. Committed to rigorous clinical research and development, the company collaborates with healthcare professionals to bring forth effective and safe treatment options, enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Yerevan, , Armenia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials